Zevra Therapeutics Announces Resubmission Of Arimoclomol New Drug Application To The U.S. Food And Drug Administration
Read the full statement from Zevra Therapeutics here:
Here is a summary of the article:
Zevra Therapeutics Resubmits NDA for Arimoclomol: Zevra is a rare disease therapeutics company that has developed arimoclomol, an investigational drug for the treatment of Niemann-Pick disease type C (NPC), a genetic and fatal neurological disorder.
Zevra Prepares for Commercial Launch of Arimoclomol: Zevra is accelerating its launch preparations in anticipation of FDA approval and aims to bring arimoclomol to the NPC community as soon as possible.
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia: